GlassScriptPhysician profile
Mahesh D Chandra
NPI 1013925866
$556.83
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $120.12 | 2019 | |
| Sanofi-Aventis U.S. LLC | $87.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $59.16 | 2019 | |
| Pfizer INC. | $42.57 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $28.40 | 2019 | |
| Philips North America LLC | $28.05 | 2019 | |
| Lilly USA, LLC | $27.41 | 2019 | |
| Amarin Pharma, INC. | $24.95 | 2019 | |
| Glaxosmithkline, LLC. | $24.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.75 | 2019 | |
| Amgen INC. | $14.99 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.62 | 2019 | |
| Genentech USA, INC. | $14.13 | 2019 | |
| Allergan, INC. | $12.74 | 2019 | |
| Sanofi Pasteur INC. | $12.60 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.55 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahesh Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.